TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16752255

Group type: EXPERIMENTAL
Intervention: AUDIT and TLFB screening
Number of subjects: 315

Group type: COMPARATOR
Intervention: Regular antenatal care
Number of subjects: 315
Study: 15209605

Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg twice daily for 6 months
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg twice daily for 12 months
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 11270027

Group type: COMPARATOR
Intervention: 1.0 mL 0.9% saline (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1.0 mL 1% lidocaine (Group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1.0 mL dexamethasone (4 mg) (Group C)
Number of subjects: 30
Study: 9266515

Group type: EXPERIMENTAL
Intervention: pravastatin (10-40 mg/day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: lovastatin (20-80 mg/day)
Number of subjects: 45
Study: 8338047

Group type: EXPERIMENTAL
Intervention: Serum retinol concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Malaria parasite density
Number of subjects: 0
Study: 3334238

Group type: EXPERIMENTAL
Intervention: Primary suture
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Carbon fibre augmentation
Number of subjects: 57

Group type: COMPARATOR
Intervention: Primary suture vs Carbon fibre augmentation
Number of subjects: 57
Study: 31926158

Group type: EXPERIMENTAL
Intervention: Prophylactic air-extraction catheter (intervention group)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Routine chest tube drainage (control group)
Number of subjects: 96
Study: 31058571

Group type: EXPERIMENTAL
Intervention: 3D laparoscopy
Number of subjects: 68

Group type: COMPARATOR
Intervention: 2D laparoscopy
Number of subjects: 68
Study: 28456090

Group type: EXPERIMENTAL
Intervention: CTCs ≥2 at D0
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: CTCs ≥2 at D28
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: CTC count groups (low/low, high/low, low-high/high) based on D0 and D28
Number of subjects: 106
Study: 26590418

Group type: EXPERIMENTAL
Intervention: Personalized dietary intervention based on machine-learning algorithm
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 800
Study: 22402617

Group type: EXPERIMENTAL
Intervention: SRP + DL (scaling, root planing, and diode laser treatment)
Number of subjects: 36

Group type: COMPARATOR
Intervention: SRP (scaling and root planing only)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: SRP + DL
Number of subjects: 36

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 36
Study: 21784351

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 2528

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 2528

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2528

Group type: EXPERIMENTAL
Intervention: NSAIDs (Naproxen and Celecoxib)
Number of subjects: 2528
Study: 19548010

Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer cement (Vitrebond)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer cement (Fuji Lining LC)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Calcium hydroxide cement (Dycal)
Number of subjects: 27
Study: 16449338

Group type: EXPERIMENTAL
Intervention: Cortistatin-17
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Somatostatin-14
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study: 15229915

Group type: EXPERIMENTAL
Intervention: Ultrasound dating at 12-14 weeks
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Ultrasound dating at 15-20 weeks
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Three dating formulae
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Two dating formulae
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Five dating formulae
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Early scanning
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Mean true gestational age at delivery in IVF pregnancies
Number of subjects: 363
Study: 11596834

Group type: EXPERIMENTAL
Intervention: Stratified care (including zolmitriptan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stepped care
Number of subjects: 0
Study: 9466100

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.15 mg kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vecuronium 0.1 mg kg‐1
Number of subjects: 30
Study: 7933026

Group type: EXPERIMENTAL
Intervention: Doppler sonography at proximal location
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Doppler sonography at distal location
Number of subjects: 47
Study: 3351267

Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate
Number of subjects: 575

Group type: COMPARATOR
Intervention: povidone‐iodine solution
Number of subjects: 575

Group type: COMPARATOR
Intervention: medicated bar soap
Number of subjects: 575
Study: 29385024

Group type: EXPERIMENTAL
Intervention: Lifelong Improvements through Fitness Together (LIFT)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Stay Strong; Stay Healthy (SSSH)
Number of subjects: 113
Study: 27716209

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (10-weekly intramuscular injections for 56 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 24157087

Group type: EXPERIMENTAL
Intervention: Family Motivational Intervention (FMI)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Routine Family Support (RFS)
Number of subjects: 97
Study: 22462423

Group type: EXPERIMENTAL
Intervention: ETN + MTX
Number of subjects: 300

Group type: COMPARATOR
Intervention: DMARD + MTX
Number of subjects: 300
Study: 21353106

Group type: EXPERIMENTAL
Intervention: Pregabalin (150-600 mg/d)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 18027048

Group type: EXPERIMENTAL
Intervention: Sickle cell disease patients (group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal patients without SCD (control group, group 1)
Number of subjects: 30
Study: 16680957

Group type: EXPERIMENTAL
Intervention: Combined FE enzymes (50 ml dissolved in 0‐150 ml normal saline to reach the final concentration of 1‐3 U/ml)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined FE enzymes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 30
Study: 12503230

Group type: EXPERIMENTAL
Intervention: Community Empowerment and Nutrition Program (CENP)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Comparison group (no specific intervention mentioned)
Number of subjects: 240
Study: 9504644

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Oestrogen-progesterone combinations
Number of subjects: 300

Group type: COMPARATOR
Intervention: Oestrogen monotherapy
Number of subjects: 300
Study: 7991068

Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal peptide (VIP) 100 micrograms
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Peptide histidine methionine (PHM) 100 micrograms
Number of subjects: 22
Study: 3052668

Group type: EXPERIMENTAL
Intervention: General practitioner intervention with advice and information on reducing alcohol consumption, including a drinking diary.
Number of subjects: 909
Study: 30714689

Group type: EXPERIMENTAL
Intervention: System-based intervention including a real-time warning system, race-specific feedback, and a nurse navigator.
Number of subjects: 360

Group type: COMPARATOR
Intervention: Retrospective control group
Number of subjects: 360
Study: 28183036

Group type: EXPERIMENTAL
Intervention: Scalp block
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Local anesthetic infiltration (bupivacaine 0.5%)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (remifentanil)
Number of subjects: 47
Study: 23432894

Group type: EXPERIMENTAL
Intervention: Intervention (change of positioning and stimulation of cough)
Number of subjects: 42
Study: 21828339

Group type: EXPERIMENTAL
Intervention: Breakfast (Day BL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lunch after breakfast (Day BL)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lunch without breakfast (Day FL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Insulin and C-peptide response
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 12
Study: 19126625

Group type: EXPERIMENTAL
Intervention: 25 mg HPLC‐purified DHEA/d orally for 12 months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 17124720

Group type: EXPERIMENTAL
Intervention: DiaPep277 (1 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: DiaPep277
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: DiaPep277 (after extension)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (after extension)
Number of subjects: 35
Study: 14984446

Group type: EXPERIMENTAL
Intervention: Church-based diabetes risk reduction programme
Number of subjects: 516
Study: 11881266

Group type: EXPERIMENTAL
Intervention: Sensation and Distress of Pain Visual Analogue Scales (VAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual numerical rating scales (NRS)
Number of subjects: 0
Study: 9609376

Group type: EXPERIMENTAL
Intervention: ePTFE membranes
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cellulose membranes
Number of subjects: 15
Study: 7811056

Group type: EXPERIMENTAL
Intervention: Dapsone 100 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Dapsone 100 mg with 30 ml high potency antacid
Number of subjects: 7
Study: 2809052

Group type: EXPERIMENTAL
Intervention: Prompted voiding treatment (hourly checks, asking for toileting assistance, social reinforcement)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Prompted voiding treatment
Number of subjects: 126
Study: 31971279

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (TUS) applied to the lumbar region for 10 minutes (frequency, 1 MHz; intensity, 1.5 W/cm2; effective irradiation area of the transducer head, 5 cm2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Physiotherapy modalities (superficial heating and transcutaneous electrical nerve stimulation) and exercise therapy
Number of subjects: 40
Study: 30585257

Group type: EXPERIMENTAL
Intervention: HD-FOLFIRI (irinotecan dose 300 mg/m2 for UGT1A1*1/*1 and 260 mg/m2 for *1/*28)
Number of subjects: 82

Group type: COMPARATOR
Intervention: FOLFIRI (irinotecan dose 180 mg/m2)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: HD-FOLFIRI
Number of subjects: 82

Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: HD-FOLFIRI and FOLFIRI
Number of subjects: 82
Study: 28243021

Group type: EXPERIMENTAL
Intervention: modified L‐haptic IOL
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: modified C‐haptic IOL
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: plate‐haptic IOL
Number of subjects: 150

Group type: COMPARATOR
Intervention: All IOLs
Number of subjects: 150
Study: 25980699

Group type: EXPERIMENTAL
Intervention: Virtual Cardiac Rehabilitation Program (vCRP)
Number of subjects: 22
Study: 24804018

Group type: EXPERIMENTAL
Intervention: 250 mg Wellmune WGP(R) beta‐1,3/1,6‐Glucan daily for 4 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: 250 mg placebo (rice flour) daily for 4 weeks
Number of subjects: 48
Study: 22068444

Group type: EXPERIMENTAL
Intervention: Daily sport activity during the school day (1 hour of regulated sport exercise, including 15 min of endurance training, five days a week)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Customary sport activity (two hours a week)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Daily sport activity during the school day
Number of subjects: 232
Study: 19935991

Group type: EXPERIMENTAL
Intervention: Percutaneous adhesiolysis with targeted delivery and injection of lidocaine, 10% hypertonic sodium chloride solution, and non‐particulate Betamethasone.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Caudal epidural injections with catheterization up to S3 with local anesthetic, 0.9% sodium chloride solution, non‐particulate betamethasone.
Number of subjects: 50
Study: 16467120

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of Anastrozole and Tamoxifen
Number of subjects: 0
Study: 15936866

Group type: EXPERIMENTAL
Intervention: Naltrexone (opiate antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12496531

Group type: EXPERIMENTAL
Intervention: Ductal occlusion with fibrin glue
Number of subjects: 182

Group type: COMPARATOR
Intervention: No ductal occlusion (control)
Number of subjects: 182
Study: 10636456

Group type: EXPERIMENTAL
Intervention: Subcutaneous enoxaparin (40 mg once daily)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 7777109

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 micrograms/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 2131899

Group type: EXPERIMENTAL
Intervention: Nicardipine administered at doses of 10 mg/h, 12.5 mg/h, and 15.0 mg/h for 5 minutes, 5 minutes, and 15 minutes, respectively.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Nicardipine during maintenance period at an infusion rate reduced to 3.0 mg/h, adjusted by 1.0 to 2.5 mg/h every 15 minutes as needed.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Baseline measurement of plasma norepinephrine (NE) concentrations prior to nicardipine infusion.
Number of subjects: 7

Group type: COMPARATOR
Intervention: Nicardipine treatment.
Number of subjects: 7
Study: 355601

Group type: EXPERIMENTAL
Intervention: Sodium valproate 1200 mg daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31630899

Group type: EXPERIMENTAL
Intervention: Implementation intention intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 90
Study: 30878623

Group type: EXPERIMENTAL
Intervention: mHealth augmented social support training (daily text-messages that synchronize with the patient messages)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Pamphlet based training (same content mailed to their house)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: mHealth augmented social support training
Number of subjects: 166

Group type: COMPARATOR
Intervention: Pamphlet based training
Number of subjects: 166
Study: 29188878

Group type: EXPERIMENTAL
Intervention: 150 min/week brisk walking program for six months (n=61)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group with physical activity allowed freely (n=60)
Number of subjects: 121
Study: 25965641

Group type: EXPERIMENTAL
Intervention: Soft liner with silver zeolite (SZ)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Soft liner without silver zeolite (S)
Number of subjects: 30
Study: 24273967

Group type: EXPERIMENTAL
Intervention: Chinese medical treatment (Shen invigorating and blood activating, Shen invigorating and Pi supplementing, Shen‐qi benefiting)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Western medical treatment (Clomifene, 25 mg per day)
Number of subjects: 128
Study: 21574782

Group type: EXPERIMENTAL
Intervention: 400 IU cholecalciferol by filmstrip
Number of subjects: 43

Group type: COMPARATOR
Intervention: 400 IU cholecalciferol by dropper (1 mL syrup)
Number of subjects: 43
Study: 19619896

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 682
Study: 16723246

Group type: EXPERIMENTAL
Intervention: Cold blood with hot shot (CB+HS)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Cold blood (CB)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Intermittent antegrade cold crystalloid (CC)
Number of subjects: 103
Study: 15257742

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD) used in regenerative periodontal surgery
Number of subjects: 166
Study: 11216500

Group type: EXPERIMENTAL
Intervention: Wheat bran biscuit (7.5 g/day) for 12 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Wheat bran biscuit (15 g/day) for 12 weeks
Number of subjects: 12
Study: 9328383

Group type: EXPERIMENTAL
Intervention: Bassini‐Stetten repair for group I (firm posterior wall)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Ring narrowing for group I (firm posterior wall)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Bassini‐Stetten repair for group II (weakened posterior wall)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Shouldice repair for group II (weakened posterior wall)
Number of subjects: 365
Study: 8222484

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 4038159

Group type: EXPERIMENTAL
Intervention: Fish oil supplement (15 g daily for 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vegetable oil supplement (15 g daily for 4 weeks)
Number of subjects: 20
Study: 30851442

Group type: EXPERIMENTAL
Intervention: Ceritinib 450 mg with food
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Ceritinib 600 mg with food
Number of subjects: 306

Group type: COMPARATOR
Intervention: Ceritinib 750 mg fasted
Number of subjects: 306
Study: 28805780

Group type: EXPERIMENTAL
Intervention: TEA (Thoracic Epidural Anesthesia)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: PVB (Paravertebral Blockade)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: ICB (Intercostal Blockade)
Number of subjects: 300
Study: 24814892

Group type: EXPERIMENTAL
Intervention: 50:50 mixture of PepGen P‐15® and OsteoGraf®/N‐700 (test group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: BioOss® (control group)
Number of subjects: 24
Study: 24301237

Group type: EXPERIMENTAL
Intervention: Full-face injections of abobotulinum toxin A (ABO) at doses of 120-165 U
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Full-face injections of abobotulinum toxin A (ABO) at doses of 166-205 U
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Full-face injections of abobotulinum toxin A (ABO) at doses of 206-250 U
Number of subjects: 90
Study: 22080324

Group type: EXPERIMENTAL
Intervention: Betaine (2.5 g mixed in 500 ml of Gatorade®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (500 ml of Gatorade®)
Number of subjects: 0
Study: 19878590

Group type: EXPERIMENTAL
Intervention: budesonide/formoterol (400/12 microg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone (50/500 microg)
Number of subjects: 55
Study: 17121555

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT)
Number of subjects: 60
Study: 14691990

Group type: EXPERIMENTAL
Intervention: 18-g needle
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 20-mL syringe
Number of subjects: 100

Group type: COMPARATOR
Intervention: 20-g needle
Number of subjects: 100

Group type: COMPARATOR
Intervention: 5-mL syringe
Number of subjects: 100
Study: 11425979

Group type: EXPERIMENTAL
Intervention: Multiphasic, contrast-enhanced, multi-detector row CT during the pancreatic parenchymal phase (PPP)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Multiphasic, contrast-enhanced, multi-detector row CT during the portal venous phase (PVP)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Multiphasic, contrast-enhanced, multi-detector row CT during the arterial phase (AP)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Combination of PPP and PVP imaging
Number of subjects: 77

Group type: COMPARATOR
Intervention: Arterial phase (AP) imaging
Number of subjects: 77
Study: 9504575

Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger changed every 24 hours
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger changed every 48 hours
Number of subjects: 29

Group type: COMPARATOR
Intervention: Heated humidifier system changed every 48 hours
Number of subjects: 29
Study: 8109895

Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham radiation (Control)
Number of subjects: 30
Study: 3294371

Group type: EXPERIMENTAL
Intervention: Rice powder-based ORS
Number of subjects: 60
Study: 30358109

Group type: EXPERIMENTAL
Intervention: Golimumab (anti-TNF antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mavrilimumab (GM-CSF receptor antibody)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Golimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mavrilimumab
Number of subjects: 0
Study: 28546090

Group type: EXPERIMENTAL
Intervention: Cabotegravir (800 mg intramuscular injections every 12 weeks)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo (saline injections every 12 weeks)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Cabotegravir (800 mg intramuscular injections)
Number of subjects: 127
Study: 25705822

Group type: EXPERIMENTAL
Intervention: Peanut consumption until 60 months of age
Number of subjects: 640

Group type: COMPARATOR
Intervention: Peanut avoidance until 60 months of age
Number of subjects: 640
Study: 24107588

Group type: EXPERIMENTAL
Intervention: CXL-1020 (50-500 μmol/L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CXL-1020
Number of subjects: 0
Study: 21190995

Group type: EXPERIMENTAL
Intervention: Partly self-administered exercise intervention
Number of subjects: 105

Group type: COMPARATOR
Intervention: Social contact control group
Number of subjects: 105
Study: 19058981

Group type: EXPERIMENTAL
Intervention: HES200/0.62
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: HES130/0.4
Number of subjects: 62

Group type: COMPARATOR
Intervention: gelatine
Number of subjects: 62
Study: 17005076

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Chinese medicine (Synthetic group)
Number of subjects: 128
Study: 12789623

Group type: EXPERIMENTAL
Intervention: LY-354740
Number of subjects: 0
Study: 10386759

Group type: COMPARATOR
Intervention: Hypothermia (28 degrees C)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Moderate hypothermia (32 degrees C)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Normothermia (37 degrees C)
Number of subjects: 66
Study: 8767945

Group type: EXPERIMENTAL
Intervention: Agee endoscopic procedure
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional open procedure
Number of subjects: 120